Aptinyx’s NYX-2925 Draws Skepticism As It Fails Another Trial

 
• By Alaric DeArment

The company is no longer pursuing development of the drug in painful diabetic peripheral neuropathy, but while more optimistic about fibromyalgia, that indication has less supporting data.

Aptinyx said its Phase IIb trial of NYX-2925 in diabetic peripheral neuropathy did not meet its primary endpoint • Source: Alamy

More from Clinical Trials

More from R&D